Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pharmacokinetic comparability study of TAK-881 versus HyQvia in adults with CIDP
2024-517450-95-00Phase 3Authorised
- Sponsor
- Takeda
- Start
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of TAK-881 and Human normal immunoglobulin G in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Takeda. Primary endpoint: Baseline-uncorrected area under the curve during the dosing interval at steady state. Planned start Jun 2025; status: authorised.
02
Drugs
TAK-881Human normal immunoglobulin G
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2024-517450-95-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517450-95-00.